Effects of Synvisc on Cartilage in Knee Osteoarthritis (OA)

Completed · Phase 1 · Has a placebo group

Conditions studied: Osteoarthritis

In brief

Hylan G-F 20 (Synvisc) is an FDA-approved hyaluronate derivative used to treat knee osteoarthritis (OA). Animal studies have shown that Synvisc can have favorable effects on cartilage when injected into joints. This study attempts to evaluate the effects of Synvisc when injected into knees of patients with knee OA by means of a specialized MRI technology (dGEMRIC).

Key facts

Study ID
NCT00949494
Run by
Endeavor Health
People needed
30
Starts
2006-09-01
Expected to finish
2009-02-01
Last updated by the study team
2019-09-10

Who can join

Age: 40 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.